SAN DIEGO, May  12, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ:TMCI). The investigation focuses on Treace&#39;s executive

TMCI

Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Treace Medical Concepts Faces Investor Investigation Following Financial Disappointment

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, May  12, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ:TMCI). The investigation focuses on Treace&amp;#39;s executive</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Treace Medical Concepts (TMCI) is under investigation amid disappointing financial results and reduced guidance, impacting investor sentiment. They reported lower-than-expected revenue growth and shifts in surgery trends affecting the Lapiplasty System. This investigation by Johnson Fistel could have implications for TMCI&#039;s stock price and investor recoveries.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel investigates potential claims for TMCI investors.</li><li>Recent financial results revealed lower growth and revised guidance.</li><li>Stock price sharply declined following announcements of disappointing performance.</li><li>Investors suffered losses amid changing surgical preferences and deferrals.</li><li>Johnson Fistel questions compliance with federal securities laws.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Treace Medical Concepts, Inc. (TMCI)</strong>: Facing legal scrutiny and market performance challenges.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This situation fits the &#039;Legal&#039; category as it involves a securities fraud investigation impacting investor rights and potential stock valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Investor loss recovery potential raises legal concerns for TMCI.</li><li>Sharp revenue decline could further pressure stock price.</li><li>Shifts toward minimally invasive procedures may impact future sales.</li><li>Lower full-year guidance signals reduced market confidence.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>TMCI reported Q3 2025 revenue growth was lower than expected.</li><li>Full-year 2025 revenue outlook is now $211M-$213M, down from $224M-$230M.</li><li>Q3 revenue included $6.0M in initial stocking orders.</li><li>Lapiplasty System sales significantly impacted by changing surgical preferences.</li><li>Smart consumer sentiment has delayed elective bunion procedures.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider reducing exposure to TMCI due to ongoing investigations and earnings pressure.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, May  12, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TMCI">TMCI</a>). The investigation focuses on Treace's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased Treace securities?</strong><br></br>If you purchased Treace securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=6FSpDcpe1LdWJhTA90m1mknuRs30ssi8SjbR4Jt7oj6AzzEgWMDIESeQIsCacr6cE5KouNWJYf0v83PR_VXJ0OR-i12MOKPH5KBahlUX7vZSCAxyds5itJ-21TqcueOVQlMacF60xQh3xJgBhqUlvUjgsws64lzWbnKfT3XnzFx-ca756gUbnWECPteb6PDe" rel="nofollow" target="_blank">Click here to join the investigation</a>.</p>  <p>Or for more information, contact Jim Baker at <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On November 6, 2025, Treace reported its third quarter 2025 financial results and revised its full-year 2025 outlook.</p>  <p>Treace disclosed that its revenue growth reflected "higher than planned sales to a limited number of stocking distributors" that the Company did "not expect to recur at the same level." The Company further disclosed that Lapiplasty volumes had been impacted as surgeon and patient preferences shifted toward minimally invasive solutions, and that broader macroeconomic conditions and softer consumer sentiment were resulting in more deferrals of elective bunion procedures.</p>  <p>In its quarterly report, Treace further disclosed that third quarter revenue growth was partially offset by lower average selling prices of its newest bunion procedure kits, and that third quarter revenue included $6.0 million in sales to stocking distributors, a majority of which was attributable to initial stocking orders.</p>  <p>In addition, Treace lowered its full-year 2025 revenue guidance to a range of $211 million to $213 million, compared to previous guidance of $224 million to $230 million. The Company stated that the reduction was primarily the result of expected lower sales from its flagship Lapiplasty System due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, lower patient demand for elective bunion surgery due to macroeconomic conditions, and other disclosed headwinds.</p>  <p>Following these disclosures, Treace's stock price declined sharply, damaging investors.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether Treace complied with the federal securities laws. If you suffered losses from your investment in Treace stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=4AisQOUzcYUPF7FmHKh34UNK0l3rcs__zpz_Y9eVPEk4VlTONfYz9_5BxuFtXJkpA04VQwQOVfvjSPxUKDV5hPS9_qbVVKwJw0FMBztK_58=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxODMwNyM3NTk3MDIyIzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZDkwYmU1NmMtZmVjMi00NTI5LWEyMTUtMjMwNTFjM2RhYjU0LTExOTMzNTgtMjAyNi0wNS0xMi1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Treace Medical Concepts (TMCI) is under investigation amid disappointing financial results and reduced guidance, impacting investor sentiment. They reported lower-than-expected revenue growth and shifts in surgery trends affecting the Lapiplasty System. This investigation by Johnson Fistel could have implications for TMCI's stock price and investor recoveries.

Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News